MSB 1.40% $1.09 mesoblast limited

MSB 2022 - The road to commercialisation, page-1057

  1. 24 Posts.
    lightbulb Created with Sketch. 34

    Whytee, sounds like you are short on Meso. Your push to Sell is crystal clear.

    I do have to congratulate all the short sellers though. They have totally decimated the share price and made huge amounts of money. Worth noting though it’s already up more than 20% since its lows only a few days ago..

    My suggestion to all short sellers is to be very careful if you have a short position as your day in the sun may be closing in sooner than you think.

    Whytee, As for your negative comment on what a disaster the potency issue has turned out to be

    Perhaps you could explain to everyone why the treatment for hematologic malignancies using hematopoietic stemcell transplants derived from peripheral blood, cord blood or bone marrow received Japanese Government regulatory approval for its mesenchymal stemcell-based product for children and adults with acute graft versus host disease in 2018. Yes Full approval in Japan since 2018. And the sales continue to grow !.

    I'm guessing that you probably think the Japanese are stupid saving lives !!!
    Do you think the FDA may be behind the times ???

    Or perhaps like many have already suggested there is serious corruption slowing the process !!

    Plenty going on in the background at Meso.
    Good luck to all those still holding or buying.

    Last edited by Spindrift: 06/07/22
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.09
Change
0.015(1.40%)
Mkt cap ! $1.238B
Open High Low Value Volume
$1.11 $1.12 $1.08 $5.330M 4.863M

Buyers (Bids)

No. Vol. Price($)
29 201857 $1.08
 

Sellers (Offers)

Price($) Vol. No.
$1.09 75084 9
View Market Depth
Last trade - 11.43am 03/05/2024 (20 minute delay) ?
Last
$1.09
  Change
0.015 ( 1.85 %)
Open High Low Volume
$1.10 $1.12 $1.08 757577
Last updated 12.03pm 03/05/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.